AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-14 and is reviewed periodically as new material appears.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
The delayed time to peak levels (2–3 hours) and long elimination half-life (12 hours) of suvorexant are less than ideal for an insomnia medication as they result in a delayed onset of effect and significant next-day side effects such as daytime sedation. Orexin receptor antagonists with shorter half-lives and faster onsets of action are theoretically more optimal for therapeutic use as sleep aids. The ideal insomnia medication would not have a duration of action extending beyond about 8 hours. Relative to suvorexant, daridorexant has a shorter half-life (8 hours) while lemborexant has a longer half-life (17–55 hours). However, although lemborexant has a longer terminal elimination half-life than suvorexant, it appears to be more rapidly cleared in the earlier phases of elimination. The investigational agents seltorexant and vornorexant, which are still in clinical trials, have comparatively very short half-lives in the range of 1.5 to 3 hours.
Geography, demography, and tradition contributed to this outcome but did not determine it. It took men, responding unpredictably to circumstances, to forge the chain of causation; and it took [Stalin] in particular, responding predictably to his own authoritarian, paranoid, and narcissistic predisposition, to lock it into place. According to Leffler, the most distinctive feature of We Now Know is the extent to which Gaddis "abandons post-revisionism and returns to a more traditional interpretation of the Cold War". Gaddis is now widely seen as more "orthodox" than "post-revisionist". The revisionist Bruce Cumings had a high-profile debate with Gaddis in the 1990s, where Cumings criticized post-revisionism generally and Gaddis in particular as moralistic and lacking in historical rigor. Cumings urged post-revisionists to employ modern geopolitical approaches like world-systems theory in their work. Other post-revisionist accounts focus on the importance of the settlement of the German Question in the scheme of geopolitical relations between the United States and the Soviet Union.
== Research == Low-allergen foods are being developed, as are improvements in skin prick test predictions; evaluation of the atopy patch test, wasp sting outcomes predictions, a rapidly disintegrating epinephrine tablet, and anti-IL-5 for eosinophilic diseases.
Sources: en.wikipedia.org
==== Sliding scales ==== First described in 1934, what physicians typically refer to as sliding-scale insulin (SSI) is fast- or rapid-acting insulin only, given subcutaneously, typically at meal times and sometimes bedtime, but only when blood glucose is above a threshold (e.g. 10 mmol/L, 180 mg/dL). The so-called "sliding-scale" method is widely taught, although it has been heavily criticized. Sliding scale insulin (SSI) is not an effective way of managing long-term diabetes in individuals residing in nursing homes. Sliding scale insulin leads to greater discomfort and increased nursing time.
== Arrival of the Russian army in Abkhazia == On 3 August 2008, Ogoniok reported that journalist had witnessed Russian military convoy entering Abkhazia on the Russo-Abkhaz border in late July 2008. There had been non-stop movement of the railway echelons in Abkhazia several weeks earlier and that between forty-five and fifty railway cars with tanks had entered the Gali district on the Abkhaz-Georgian border. It also reported that the quantity of armaments and ammunition in Abkhazia was enough to wage a conflict for several years. An unnamed Russian colonel from the peacekeeping forces told journalist that he was expecting that "something will happen." Journalist witnessed that "special-looking" men were crossing the Russo-Abkhaz border. Abkhaz leader Sergei Bagapsh said to journalist: "We are ready for the war, but I am not about to tell the whole world in detail how we have prepared ourselves." Abkhaz leader also commented on the Georgian presence in the Kodori Valley, "You know, we can not indefinitely tolerate their antics in our backyard. It is time to put things in order there." Although Bagapsh had hinted at something, he added that the Abkhaz would never shoot first towards Georgia. In January 2015, resident of Sochi, Oksana Sevastidi, was arrested for treason. She had sent a SMS to the Georgian friend in 2008 in which she reported on the movement of the Russian troops by the railroad to the Abkhaz border before the war. In March 2015, the Supreme Court of Russia reviewed a case of a woman from Sochi, who was accused of treason.
====== Graduate programs in cosmetic science ====== The interdisciplinary cosmetic science programs provide opportunities to develop professional skills and fundamental concepts driving cosmetic science. Started in 1973, the college's MS in Cosmetic Science is one of the oldest such graduate programs in the world. The Graduate programs in cosmetic science are as follows:
Sources: en.wikipedia.org
Some of the earliest human remains found in the Americas, Luzia Woman, were found in the area of Pedro Leopoldo, Minas Gerais, and provide evidence of human habitation going back at least 11,000 years. The earliest pottery ever found in the Western Hemisphere was excavated in the Amazon basin of Brazil and radiocarbon dated to over 8,000 years ago (6000 BC). The pottery was found near Santarém and provides evidence that the region supported a complex prehistoric culture. The Marajoara culture flourished on Marajó in the Amazon delta from AD 400 to 1400, developing sophisticated pottery, social stratification, large populations, mound building, and complex social formations such as chiefdoms. Around the time of the Portuguese arrival, the territory of present day Brazil had an estimated Indigenous population of 7 million people, mostly semi-nomadic, who subsisted on hunting, fishing, gathering, and migrant agriculture. The population comprised several large Indigenous ethnic groups (e.g., the Tupis, Guaranis, and Gês. The Tupi people were subdivided into the Tupiniquins and Tupinambás. Before the arrival of the Europeans, the boundaries between these groups and their subgroups were marked by wars that arose from differences in culture, language and moral beliefs. These wars also involved large-scale military actions on land and water, with cannibalistic rituals on prisoners of war. While heredity had some weight, leadership was a status more won over time than assigned in succession ceremonies and conventions.
Smooth muscle cell proliferation is one of important mechanisms of hypertensive remodeling of blood vessels and their stenosis, so it is an important pathogenetic mechanism in arterial hypertension and atherosclerosis. Endogenous sulfur dioxide in low concentrations causes endothelium-dependent vasodilation. In higher concentrations it causes endothelium-independent vasodilation and has a negative inotropic effect on cardiac output function, thus effectively lowering blood pressure and myocardial oxygen consumption. The vasodilating and bronchodilating effects of sulfur dioxide are mediated via ATP-dependent calcium channels and L-type ("dihydropyridine") calcium channels. Endogenous sulfur dioxide is also a potent antiinflammatory, antioxidant and cytoprotective agent. It lowers blood pressure and slows hypertensive remodeling of blood vessels, especially thickening of their intima. It also regulates lipid metabolism. Endogenous sulfur dioxide also diminishes myocardial damage, caused by isoproterenol adrenergic hyperstimulation, and strengthens the myocardial antioxidant defense reserve.
== Testing == The meat industry strives to produce meat with standardized and guaranteed tenderness, since these characteristics are sought for by the consumers. For that purpose a number of objective tests of tenderness have been developed, gauging meat resistance to shear force, most commonly used being Slice Shear Force test and Warner–Bratzler Shear Force test.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.